Canada approves expanded use of Vertex's cystic fibrosis treatment Trikafta for kids aged 6-11
Zerbor/iStock via Getty Images


Vertex Pharmaceuticals (NASDAQ:VRTX) on Wednesday said Canada approved the expanded use of the company's cystic fibrosis treatment Trikafta to include children aged 6-11 years.
VRTX said Health Canada granted a marketing authorization for the expanded use of Trikafta to include 6-11 year old children with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

The company said the expanded use approval means about 500 Canadians aged 6-11 are now eligible for Trikafta.
VRTX earlier completed a phase 3 study which enrolled 66 children aged 6-11 with cystic fibrosis to evaluate the safety and efficacy of Trikafta.
An additional dosage strength of Trikafta tablets is now available as a result of the expanded use approval.
VRTX stock earlier closed +1% at $285.30.